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Abstract
AIM: To evaluate whether the ABO blood group is re-
lated to pancreatic cancer risk in the general population 
of the United States. 
METHODS: Using the University of Pittsburgh’s clinical 
pancreatic cancer registry, the blood donor database 
from our local blood bank (Central Blood Bank), and 
the blood product recipient database from the regional 
transfusion service (Centralized Transfusion Service) in 
Pittsburgh, Pennsylvania, we identified 274 pancreatic 
cancer patients with previously determined serological 
ABO blood group information. The ABO blood group 
frequency was compared between these patients and 
708 842 individual, community-based blood donors who 
had made donations to Pittsburgh’s Central Blood Bank 
between 1979 and 2009.
RESULTS: The frequency of blood group A was statisti-
cally significantly higher amongst pancreatic cancer pa-
tients compared to its frequency amongst the regional 
blood donors [47.63% vs  39.10%, odds ratio (OR) = 
1.43, P  = 0.004]. Conversely, the frequency of blood 
group O was significantly lower amongst pancreatic 
cancer patients relative to the community blood donors 
(32.12% vs  43.99%, OR = 0.60, P  = 0.00007). There 
were limited blood group B (n  = 38) and AB (n  = 17) 
pancreatic cancer patients; the overall P  trend value 
comparing patient to donor blood groups was 0.001.
CONCLUSION: The ABO blood group is associated with 
pancreatic cancer risk. Future studies should examine the 
mechanism linking pancreatic cancer risk to ABO blood 
group.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Pancreatic adenocarcinoma is the fourth most common 
cancer in the United States among men and women and 
has the highest case-fatality rate of  any of  the major can-
cers, due to its late stage at diagnosis and poor response to 
traditional therapies[1]. The median survival of  pancreatic 
cancer patients is about 6 mo, and the majority of  patients 
do not have resectable disease at the time of  their diagno-
sis[2]. Pancreatic cancer increases in likelihood with advanc-
ing age and predominates in certain ethnic/racial groups, 
such as African-Americans, Ashkenazi Jews, Pacific Is-
landers, and the New Zealand Maori[3]. The elevated risk 
among certain populations appears to be multifactorial 
in nature and likely is due to a combination of  environ-
mental and inherited factors. The most significant genetic 
variables that are associated with the development of  
pancreatic cancer remain to be identified, although various 
cancer syndromes and hereditary pancreatitis place indi-
viduals at significantly increased risk[4]. Cigarette smoking, 
chronic pancreatitis, diabetes mellitus and obesity are well-
established risk factors for pancreatic cancer[5]. 
Mounting evidence has demonstrated that the ABO 
blood group may also be associated with pancreatic can-
cer. A Spanish study of  108 cases and 374 controls found 
a non-significantly elevated risk of  pancreatic cancer 
among individuals with blood group A [relative risk (RR) 
= 1.52, 95% confidence interval (CI): 0.87-2.67][6]. An 
Italian series of  224 patients with histologically-confirmed 
pancreatic adenocarcinoma compared the ABO blood 
group distribution with two control groups: 7086 patients 
with various diseases (Group 1) and 7320 voluntary blood 
donors (Group 2). The researchers noted an increased 
incidence of  pancreatic cancer among the blood group 
B patients (RR = 1.5 vs Group 1, P = 0.021; RR = 1.7 vs 
Group 2, P = 0.0025) and a decreased number in blood 
group O patients, when compared with the two control 
groups[7]. Additionally, a combined, prospective cohort 
study of  over 107 000 US health professionals observed 
that blood groups A, B, and AB were associated with an 
overall increased risk of  developing pancreatic cancer[8]. 
More recently, a genome-wide association study (GWAS) 
of  1896 individuals with pancreatic cancer and 1939 con-
trols - validated using an additional 2457 affected individu-
als and 2654 controls - identified a single nucleotide poly-
morphism (SNP) in intron 1 of  the ABO gene (rs505922) 
as a genetic risk factor for pancreatic cancer [odds ratio 
(OR) = 1.20; 95% CI: 1.12-1.28][9]. In an effort to further 
discern how pancreatic cancer and the ABO blood group 
might be associated, we investigated the relationship of  
pancreatic cancer incidence with ABO blood group in 
our Western Pennsylvania regional population. We com-
pared the serologically-determined ABO blood group of  
pancreatic cancer patients with the ABO group of  greater 
than 700 000 blood donors to the Central Blood Bank in 
Pittsburgh.
MATERIALS AND METHODS
To estimate the ABO frequencies in our local area, the 
donor database of  the Central Blood Bank in Pittsburgh, 
Pennsylvania was queried for the ABO group of  individual 
donors. The Central Blood Bank collects blood mainly in 
southwestern Pennsylvania. This database includes all in-
dividuals who have made a blood donation to the Central 
Blood Bank over the past approximately 30 years. Between 
1979 and 2009, there were 708 842 unique blood donors. 
Pancreatic cancer patients from the University of  Pitts-
burgh’s affiliated hospitals - Presbyterian University Hos-
pital and the University of  Pittsburgh Cancer Institute’s 
Hillman Cancer Center - who had provided informed con-
sent to be part of  their pancreatic cancer research registry 
were included in this study. Of  359 eligible pancreatic 
cancer patients in the registry, 274 had a historical or cur-
rent ABO blood group available after querying the Cen-
tralized Transfusion Service’s database. The Centralized 
Transfusion Service’s database includes all patients who 
have a type and screen performed at Pittsburgh area hos-
pitals. Blood donors were screened for infectious diseases 
according to Food and Drug Administration (FDA) and 
American Association of  Blood Banks (AABB) regula-
tions. FDA approved manual and automated ABO group-
ing methods and reagents were employed both at the 
Central Blood Bank and at the Centralized Transfusion 
Service. Proportions of  ABO blood groups for pancreatic 
cancer cases and regional blood donors were compared 
using Chi-squared analysis. Data analysis was performed 
using R Project software (www.r-project.org).
RESULTS
Table 1 shows the OR of  the ABO blood group distribu-
tion of  the 274 pancreatic cancer patients in comparison 
with the ABO groups of  the 708 842 unique blood donors 
to the Central Blood Bank in the Pittsburgh area over ap-
proximately the past 30 years. The frequency of  blood 
group A was statistically significantly higher amongst the 
pancreatic cancer patients compared to the frequency 
amongst the regional blood donors. Conversely, the fre-
quency of  blood group O was statistically significantly 
lower amongst the pancreatic cancer patients relative to the 
community blood donors. 
Statistically significant associations were not revealed 
among the limited number of  blood group B (n = 38) and 
AB (n = 17) pancreatic cancer patients and regional blood 
donors; the overall P trend value comparing patient to do-
nor ABO blood groups was 0.001.
DISCUSSION
Our study demonstrates that pancreatic cancer patients 
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treated at a large, US institution are significantly more 
likely to be blood group A than regional blood donors 
and are significantly less likely to be blood group O than 
regional blood donors; the proportions of  patient vs do-
nor ABO blood groups were statistically different from 
what would be expected by chance alone. We examined 
this relationship among over 700 000 unique individuals 
who made blood donations to the Central Blood Bank in 
Pittsburgh between 1979 and 2009. Although there was 
a trend for risk of  pancreatic adenocarcinoma in associa-
tion with blood groups B and AB, a statistically significant 
effect was not observed, likely due to limited study power 
for detecting differences in these small subpopulations of  
individuals. 
In a prospective cohort study published in 2009 of  
107 503 US residents derived from the Nurses’ Health 
Study (77 360 eligible female nurses) and the Health Pro-
fessionals Follow-up Study (30 143 eligible male health 
professionals), individuals with blood group A, B and AB 
were noted overall to have an elevated risk of  pancreatic 
cancer compared to those participants with blood group 
O[8]. However, taking each study separately, only blood 
group B was associated with increased cancer risk. No-
tably, blood group was self-reported in that prospective 
study, although a validation analysis displayed a greater 
than 90% concordance rate between reported and actual 
ABO blood group. In our study, the presence of  serologi-
cally-determined blood group information from the blood 
bank was an entry criterion; thus, there was no possibility 
of  recall bias influencing our results. 
The ABO locus is located on chromosome 9 and there 
are three main alleles in the system: A101, B101, and O01[10]. 
The A101 allele encodes a glycosyltransferase that adds a 
terminal α-N-acetylgalactosamine to H antigen, produc-
ing the A antigen. Similarly the B101 allele encodes a gly-
cosyltransferase that adds a terminal α-D-galactose to H 
antigen, thus creating the B antigen. The most common 
types of  O alleles contain a critical 1-bp deletion compared 
to the consensus A101 allele and, if  translated, would give 
rise to non-functional enzymes[10,11]. In a group O individu-
al, the H antigen is not modified. In addition to studies of  
pancreatic cancer, numerous past studies have shown that 
blood group A is related to gastric cancer[12,13]. The precise 
biological reasons as to why there is a relationship between 
ABO blood group and certain cancers are unknown, al-
though two recent GWAS demonstrated that particular 
SNPs at the ABO locus were associated with the inflam-
matory cytokines tumor necrosis factor[14] and intercellular 
adhesion molecule 1[15]. The ABO blood group has also 
been shown to be related to other biological processes; for 
example, although a definitive mechanism has not yet been 
elucidated, levels of  von Willebrand factor (vWF) antigen 
have been statistically shown to correlate to the ABO 
group with group AB individuals demonstrating the high-
est average vWF levels and group O individuals having the 
lowest average vWF levels[16]. 
The ABO blood group is genetically-determined and 
therefore is not a modifiable risk factor as are cigarette 
smoking, body mass index, diet or other lifestyle-related 
variables. The risk of  pancreatic cancer for individuals 
with blood group A has been replicated in several studies. 
Nonetheless, the magnitude of  risk is not high enough to 
warrant clinical screening, especially considering that these 
approaches are still in the developing stages[17]. However, 
the risk of  pancreatic cancer in individuals with blood 
group A (and likely B or AB) is nearly as strong as the 
risk of  developing pancreatic cancer as a consequence 
of  cigarette smoking; thus, the combination of  multiple 
moderate risk factors (such as age and family history[18]) 
could be used to calculate whether some individuals are at 
high enough risk to warrant counseling for risk reduction 
strategies or inclusion in pancreatic cancer screening trials. 
The importance of  the ABO blood group in assessing 
pancreatic cancer risk is also highlighted by the lack of  
other global genetic risk factors identified in the GWAS 
by Amundadottir et al[9]. This study indicates that the etiol-
ogy of  pancreatic cancer is more complex than previously 
believed and likely represents an array of  deleterious path-
ways. Although the mechanisms of  pancreatic cancer on-
cogenesis have not been fully deciphered, the association 




Pancreatic adenocarcinoma has the highest case-fatality rate of any of the 
major cancers. Because there are no accepted population-based screening 
methods, identifying individuals at greatest risk of developing this lethal form of 
cancer is paramount to developing risk reduction strategies. Previous evidence 
has indicated that ABO blood group may influence the risk of developing pan-
creatic cancer.
Research frontiers
Blood groups A, B, and/or AB have been associated with pancreatic cancer in 
a limited number of past studies. Genome-wide association studies have also 
identified a risk locus in the ABO gene. 
Innovations and breakthroughs
This study compared the frequency of ABO blood groups in a cohort of pan-
creatic cancer patients to the blood group distributions in greater than 700 000 
community-based blood donors. The authors demonstrated that blood group 
A was statistically significantly higher and blood group O was significantly less 
frequent among pancreatic cancer patients than in community blood donors. In 
contrast to many past studies, the authors used serologically-confirmed blood 
group information.
Applications
ABO blood group information is valuable in predicting who may be at risk of 
developing pancreatic adenocarcinoma and should be incorporated into risk 
stratification and surveillance studies.
5590 November 28, 2010|Volume 16|Issue 44|WJG|www.wjgnet.com
Table 1  Odds ratio of pancreatic cancer patients stratified by 





donors, n  (%)
Pancreatic cancer 
patients, n  (%)
Odds ratio vs  
other blood groups
Group A 277 133 (39.10) 131 (47.63)   1.43 (0.004)
Group B   87 252 (12.31)   38 (13.87) 1.15 (0.41)
Group AB 32 662 (4.61) 17 (6.20) 1.37 (0.19)
Group O 311 795 (43.99)   88 (32.12)         0.60 (0.000070)
Total    708 842         274 P trend patients vs 
donors = 0.001
 COMMENTS
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Peer review
The authors report an interesting study about the connection of ABO blood 
group and the development of pancreatic cancer. The paper is written well and 
good to read, the data presented clearly and the whole paper of relevance.
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